ReviewWorld journal of gastroenterology2014
Hepatitis B virus: where do we stand and what is the next step for eradication?
Review in World journal of gastroenterology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 1 synthesis or guideline pooled it, 70 citations in OpenAlex.
- Hepatitis B/C in the countries of the EU/EEA: a systematic review of the prevalence among at-risk groups.BMC infectious diseases · 2018Pooled it
- Humanized mouse model reveals the immunogenicity of Hepatitis B Virus vaccine candidates produced in CRISPR/Cas9-editedFrontiers in immunology · 2025Article
- Exploring the optimal vaccination strategy against hepatitis B virus in childhood (Review).Biomedical reports · 2023Review
- COVID-19 pandemic effects on the distribution of healthcare services in India: A systematic review.World journal of virology · 2022Article
- Diagnosis experiences from 50 hepatitis B patients in Chongqing, China: a qualitative study.BMC public health · 2021Article
- Article
- Hepatitis B Vaccination in Children With Ongoing Cancer Treatment: A Safety and Efficacy Study of Super-Accelerated Vaccination Scheme.Turkish archives of pediatrics · 2021Article
- Article
- Studies on the serological markers for hepatitis B virus infection among type 2 diabetic patients.Journal of clinical laboratory analysis · 2021Article
- Vaccination against Hepatitis B: A Scoping Review.Asian Pacific journal of cancer prevention : APJCP · 2020Article
- Review
- Prevention strategies of mother-to-child transmission of hepatitis B virus (HBV) infection.Pediatric investigation · 2020Review
- Hepatitis B vaccination coverage across India: exploring the spatial heterogeneity and contextual determinants.BMC public health · 2019Article
- Evaluation of HBV-Like Circulation in Wild and Farm Animals from Brazil and Uruguay.International journal of environmental research and public health · 2019Article
- Hepatitis B virus (HBV) infection amongst children in Senegal: current prevalence and seroprotection level.The Pan African medical journal · 2019Article
- Efficient inhibition of duck hepatitis B virus DNA by the CRISPR/Cas9 system.Molecular medicine reports · 2017Article
- Vaccination Coverage Disparities Between Foreign-Born and U.S.-Born Children Aged 19-35 Months, United States, 2010-2012.Journal of immigrant and minority health · 2017Article
- Progress in vaccination towards hepatitis B control and elimination in the Region of the Americas.BMC public health · 2017Article
- Viral hepatitis and hepatocellular carcinoma: etiology and management.Journal of gastrointestinal oncology · 2017Review
- In Vitro Enzymatic and Cell Culture-Based Assays for Measuring Activity of HBV RNaseH Inhibitors.Methods in molecular biology (Clifton, N.J.) · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatitis B (HB) virus (HBV) infection, which causes liver cirrhosis and hepatocellular carcinoma, is endemic worldwide. Hepatitis B vaccines became commercially available in the 1980s. The World Health Organization recommended the integration of the HB vaccine into the national immunisation programs in all countries. HBV prevention strategies are classified into three groups: (1) universal vaccination alone; (2) universal vaccination with screening of pregnant women plus HB immune globulin (HBIG) at birth; and (3) selective vaccination with screening of pregnant women plus HBIG at birth. Most low-income countries have adopted universal vaccine programs without screening of pregnant women. However, HB vaccines are not widely used in low-income countries. The Global Alliance for Vaccine and Immunization was launched in 2000, and by 2012, the global coverage of a three-dose HB vaccine had increased to 79%. The next challenges are to further increase the coverage rate, close the gap between recommendations and routine practices, approach high-risk individuals, screen and treat chronically infected individuals, and prevent breakthrough infections. To eradicate HBV infections, strenuous efforts are required to overcome socioeconomic barriers to the HB vaccine; this task is expected to take several decades to complete.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.